A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
InflaRx (IFRX) has released an update. InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a ...
InflaRx (IFRX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...
Hosted on MSN5h
EU approves life changing 'important' Alzheimer's drug which can drastically slow onsetLecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback